Race-Based Disparities in Advanced Heart Failure (AHF) Evaluation and Outcomes.

Authors

• Anjali Purohit, Michigan State University College of Human Medicine Medical Student
• Niharika Chinta, Michigan State University College of Human Medicine Medical Student
• Luke A. Laconi, Michigan State University College of Human Medicine Medical Student
• Joeita Macfield, Michigan State University College of Human Medicine Medical Student
• Maria Obeidat, Michigan State University College of Human Medicine Medical Student
• Dana Marsy, Corewell Health West
• Nabin Shrestha, Corewell Health West
• Sangjin Lee, Corewell Health West
• Michael G. Dickinson, Corewell Health West
• David A. Fermin, Corewell Health West
• Matthew Gonzalez, Corewell Health West
• Ryan Grayburn, Corewell Health West
• Milena Jani, Corewell Health West
• Eesha Purohit, Corewell Health West
• Renzo Y. Loyaga-Rendon, Corewell Health West

Document Type

Conference Proceeding

Publication Date

4-2026

Publication Title

Journal of the American College of Cardiology

Abstract

Background: Racial disparities in health care access have been described previously, but limited data exist on how these disparities manifest in end-stage heart failure patients at the time of evaluation for heart transplant (HT) or LVAD. This study evaluates racial disparities in clinical characteristics and outcomes of patients referred for AHF therapy evaluation.

Methods: All patients evaluated for AHF therapies at Corewell Health West between January 2009 and September 2024 were included. Patients were categorized by race into 3 groups: White, Black, other race. Epidemiologic and clinical characteristics were obtained. AHF evaluation outcomes were categorized as accepted, not ill enough, too ill, or not a candidate for other reasons. Comparisons were performed among racial groups.

Results: A total of 1199 patients were included in this study. Of these, 927 (77.3%) were White, 154 (12.8%) were Black, and 118 (9.9%) were other race. Significant differences were observed across groups (Table 1). White patients were older, less often female, had a higher income level, and had more ischemic cardiomyopathy. Black and other race patients were more likely to reside in urban areas, have lower socioeconomic status, and less likely to be accepted for AHF therapies.

Conclusion: Significant racial disparities exist in patients evaluated for AHF therapies. Black and other race patients were less likely to be accepted for HT or LVAD. Further study is needed to better understand and address these disparities.

Volume

87

Issue

13 Suppl

First Page

A669

Comments

American College of Cardiology 75th Annual Scientific Session & Expo, March 28-30, 2026, New Orleans, LA

Last Page

A669

Recommended Citation

Purohit A, Chinta N, Laconi LA, Macfield J, Obeidat M, Marsy D, et al. [Shrestha NM, Lee S, Dickinson MG, Fermin DR, Gonzalez M, Grayburn R, Jani M, Purohit E, Loyaga-Rendon RY]. Race-based disparities in advanced heart failure (AHF) evaluation and outcomes. J Am Coll Cardiol. 2026;87(13 Suppl):A669. doi:10.1016/j.jacc.2026.02.1756.

DOI

10.1016/j.jacc.2026.02.1756

ISSN

0735-1097